Skip to main content
Norris Cotton Cancer Center
In This Section

New Clinical Trials for February 2015

Konstantin Dragnev, Cancer Mechanism
Randomized, double-blind, multicenter, Phase 3 study comparing veliparib plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in previously untreated advanced or metastatic squamous non-small cell lung cancer

Pharmaceuticals LP
A Phase III, randomized study of AZD9291 versus platinum-based doublet chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous epidermal growth factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M Mutation within the Epidermal Growth Factor Receptor Gene (AURA3)

Bayer HealthCare
Randomized Phase II double blind study of adjuvant regorafenib vs placebo in patients with node positive esophageal cancer that completed pre-operative therapy

Phase I and randomized Phase II double blind clinical trial of cisplatin and etoposide in combination with veliparib (ABT-888) or placebo as frontline therapy for extensive stage small cell lung cancer

Peter Kaufman, Molecular Therapeutics
POLLY:Phase II pre-emptive OsciLLation of ER activitY levels through alternation of estradiol/anti-estrogen therapies prior to disease progression in ER+/HER2- advanced breast cancer

Eli Lilly, Co.
A randomized, double-blind, placebo-controlled, Phase 3 study of fulvestrant with or without LY2835219, a CDK4/6 inhibitor, for women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer

Frederick Lansigan, Molecular Therapeutics
Randomized Phase II open label study of lenalidomide R-CHOP (R2CHOP) vs RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in patients with newly diagnosed diffuse large B cell lymphoma

Lionel Lewis, Molecular Therapeutics
Bayer Corporation
A Phase I, multi-center, non-randomized, open label, parallel-group study evaluating the pharmacokinetics and safety of regorafenib (BAY 73-4506) in cancer subjects with severe renal impairment compared to a control group